Treatment of Iron Deficiency Anemia in Children with Ferric Derisomaltose

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the efficacy and safety of intravenous ferric derisomaltose in children aged 0 to less than 18 years who have iron deficiency anemia (IDA) due to non-dialysis dependent chronic kidney disease or who are intolerant or unresponsive to oral iron. The study is a prospective, open-label, multi-center trial involving 200 subjects, with specific pharmacokinetic assessments for a subset of 24 participants. Subjects will receive ferric derisomaltose at doses of either 10 mg/kg or 20 mg/kg, with a maximum dose of 1000 mg, and blood samples will be collected to analyze iron levels post-treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects \<18 years
* Informed consent and child assent, as age-appropriate, obtained before any trial- related activities and willingness to participate. LAR of the subject must sign and date the ICF (according to local requirements). The child must sign and date the CAF or provide oral assent, if required according to local requirements
* IDA caused by different etiologies such as gastrointestinal disease, NDD-CKD, or other conditions leading to IDA
* Hb concentration less than the 5th percentile for age and sex-specific reference range (Appendix B)
* Subjects with NDD-CKD (a) or who are intolerant or unresponsive to oral iron (b):

  a) Subjects with NDD-CKD:
* TSAT ≤35 % or s-ferritin \<100 ng/mL
* Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73m2
* If on ESA, receiving stable ESA regimen defined as dose adjustments no more than

  ± 20 % for ≥8 weeks prior to screening

  b) Subjects with documented history of intolerance or unresponsiveness to oral iron therapy for at least one month prior to trial enrolment.
* TSAT ≤20 % or s-ferritin \<100 ng/mL

Exclusion Criteria:

* Anemia caused by factors other than IDA according to Investigator's judgment
* S-ferritin \>600 ng/mL
* Hb ≤5.0 g/dL
* Iron overload or disturbances in utilization of iron (e.g. hemochromatosis and hemosiderosis)
* ALAT and/or ASAT \>2 times upper limit of normal (e.g. decompensated liver cirrhosis or active hepatitis)
* Pregnant or nursing female subjects. In order to avoid pregnancy, female subjects of childbearing potential have to use adequate contraception (e.g. intrauterine devices, hormonal contraceptives, or double barrier method) or be abstinent during the whole trial period and 7 days after the last dosing. Childbearing potential refers to all female subjects ≥12 years old or \<12 years old who have started menstruating
* Previous serious hypersensitivity reactions to any IV iron compounds including ferric derisomaltose
* Received an investigational drug within 30 days prior to screening
* Treatment with IV iron within 10 days prior to screening
* Treatment with blood transfusion, radiotherapy, chemotherapy or other drugs that suppress the bone marrow, and drugs which have anemia as side effect within 30 days prior to screening
* Planned elective surgery (or planned surgery during the trial period) where significant blood loss is expected within the last 30 days prior to screening
* Any non-viral infection (non-viral infection that has been fully treated before the baseline visit is accepted)
* Any other laboratory abnormality, medical condition, or psychiatric disorders which, in the opinion of the Investigator, will put the subject's disease management at risk or may result in the subject being unable to comply with the trial requirements

Where it's running

• Pharmacosmos Investigational Site
  Miami, Florida, United States Recruiting

Study contacts

• Study coordinator: Pharmacosmos A/S Clinical and Non-clinical Research
• Email: info@pharmacosmos.com
• Phone: +4559485959

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing two iron supplements for treating anemia in children

  This study tests which of two iron supplements works better for treating anemia in children.

  Recruiting Khyber Teaching Hospital · Peshawar, KPK · NCT06742528

• Impact of maternal iron deficiency on child health

  This study looks at how a lack of iron in pregnant women affects the health of their children from birth to age 7.

  Recruiting Tampere University Hospital · Tampere, Pirkanmaa · NCT06879080

• Comparing two types of intravenous iron for treating anemia in pregnant women

  This study is testing whether a new type of intravenous iron can help pregnant women with anemia feel better compared to the standard treatment.

  Recruiting Phase 3 Saskatchewan Health Authority - Regina Area · Regina, Saskatchewan · NCT05251493

• Robot-assisted magnetically controlled capsule endoscopy for iron deficiency anaemia

  This study tests a robot-guided, magnetically controlled capsule to examine the upper GI tract and small bowel in adults with iron deficiency anaemia when standard tests haven’t found a cause.

  Recruiting University of Edinburgh · Edinburgh · NCT07197424

• High- versus low-dose iron treatment for adults on peritoneal dialysis (PALaDIN)

  This project will see if higher-dose versus lower-dose iron treatment helps adults on peritoneal dialysis with iron-deficiency anaemia keep their iron and haemoglobin levels more stable.

  Recruiting Phase 3 Hull University Teaching Hospitals NHS Trust · Hull, East Riding Of Yorkshire · NCT06884280

• Using intravenous iron to treat anemia after heart surgery

  This study is testing if giving intravenous iron to patients with anemia after heart surgery can help them stay out of the hospital and feel better.

  Recruiting at 3 sites Phase 2 University Health Network, Toronto · Kingston, Ontario and 2 other locations · NCT06287619

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.